Results from the survey of the Spanish Society of...
Transcript of Results from the survey of the Spanish Society of...
Dr Raúl Embún
Thoracic Surgery Department HU Miguel Servet & HCU Lozano Blesa
IIS Aragón Zaragoza University
Surgery for lung metastases of colorrectal cancer DO WE BELIEVE IN WHAT WE DO?
Results from the survey of the Spanish Society of Thoracic Surgery
Resection of lung metastases also offers 25–35 % 5-year survival rates in carefully selected patients. Surgical R0 resection should be performed for solitary or confined liver or pulmonary metastases (II, A).
Metastatic CRC 4 Prognostic Groups with treatment implications
Lung or liver metastases are clearly resectable (R0)
At first, lung or liver metastases are not resectable (Intensive induction CT should be consider prior to potential metastasectomy)
Unresectable metastases, adequate PS and bulky, symptomatic or biologically agressive disease = intensive first-line therapy
Grupo 2
Grupo 1
Grupo 0
Grupo 3
Unresectable metastases, por PS and no present or inminent symptoms = non-intensive therapy
National Survey PULMONARY METASTASECTOMY
Survey Monkey
399 thoracic surgeons and residents of thoracic surgery
18 questions type: multiple choice, ranking y rating scale
Link (https://es.surveymonkey.com/r/cirugiametastasispulmonares)
Active period from 12/3/17 to 10/4/2017
Participation 112 (28%)
1. What is your professional experience as thoracic surgeon?
15,2%
48,2%
17,0% 19,6%
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
MIR de cirugía torácica FEA cirujano torácico desdehace menos de 10 años
FEA cirujano torácico desdehace 10 a 20 años
FEA cirujano torácico desdehace más de 20 años
Responses: 112 Omissions: 0
Thoracic Surgery Resident
Thoracic Surgeon < 10y
Thoracic Surgeon 10-20y
Thoracic Surgeon > 20y
2. How many pulmonary metasasectomy procedures do you personally perform every year?
1,8%
15,5%
59,1%
20,0%
3,6%
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
70,0%
Ninguno Menos de 10 Entre 10 y 30 Entre 31 y 50 Más de 50
Responses: 110 Omissions: 2
None <10 10-30 31-50 >50
3. How do you consider the trend of this practice over the last five years?
69,7%
23,9%
3,7% 2,8%
Ascedente
Estable
Descendente
NS/NC
Responses: 109 Omissions: 3
Upward Steady Downward N/A
4. What do you think about the frequency this procedure is being performed at present?
1,0%
24,8%
58,1%
13,3%
2,9%
Es una práctica que debería deabandonarse
Debería de hacerse de forma másselectiva de lo que se realiza en la
actualidad
La frecuencia con la que se realizame parece adecuada
Debería de indicarse en un mayornúmero de casos
NS/NC
Responses: 105 Omissions: 7
It should be banned
It should be less frequent Adequate It should be
more frequent N/A
5. In case you think this practice should be banned or performed less frequently, how do you rate the influence of the following circumstances?
Not important (1)
Slightly important
Moderately important Important
Very important
(5) N/A Rating
(1-5) n
Opposition by other thoracic surgeons 0 7 15 3 2 0 3,00 27
Opposition by other professionals (no thoracic surgeons)
1 3 6 12 5 0 3,63 27
Patient preferences 4 10 5 4 4 0 2,78 27
Really compliant recomendations by current Guidelines and literature in favor of metastasectomy
0 0 5 12 10 0 4,19 27
Responses: 27 Omissions: 0
6. What are the primary tumours more frequently behind a pulmonary metastasectomy in your department? The most frequent “1” & the less frequent “5” 1 2 3 4 5 Rating
(1-5) n
Breast 3 31 25 26 15 3,19
100
Sarcomas 4 30 26 29 11 3,13
100
Colorectal 88 1 1 0 10 1,43
100
Urologycal
1 27 37 28 7 3,13 100
Others
4 11 11 17 57 4,12 100
Responses: 100 Omissions: 12
7. How frequently do you use minimal invasive surgery for pulmonary metastasectomy?
57,0%
33,0%
1,0%
7,0% 2,0%
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
Siempre quetécnicamente es factible
En casosseleccionados, nº delesiones pulmonares
En casosseleccionados,
histología
En casosseleccionados, otros
factores
Nunca
Responses: 100 Omissions: 12
Never Selectively (histology)
Selectively (other factors)
Selectively (number mtx)
Whenever technically feasible
8. In case of a patient with a single 10 mm peripheral pulmonary metastasis with a very low probability of being palpated by VATS and favourable prognostic factors (long DFI, normal CEA, no previous liver disease), what option would you choose?
62,2%
7,1%
30,6%
0%
10%
20%
30%
40%
50%
60%
70%
Resección atípicaVATS previo marcaje
Segment. anatómicaVATS +/- marcaje
Lobectomía VATS Resección atípicatoracotomía
Segment. anatómicatoracotomía
Lobectomíatoracotomía
Responses: 98 Omission: 14
VATS Wedge after marking
VATS Anatomic Seg +/- marking
VATS Lobectomy Open Wedge Open anatomic seg Open lobectomy
85%
10% 5%
Ongoing prospective cohort study. Anatomical lung resections (n=1510)
Carcinoma de pulmón Metástasis de origen extrapulmonar Otros diagnósticos
80%
20%
Type of lung resection Wedge-Segmentectomía Lobectomía-Neumonectomía
9. In case of pulmonary metastases from colorrectal cancer, rank the following prognostic factors according to their importance in surgical decision-making. The most important “1” & the least “6”.
1 2 3 4 5 6 Ranking n CEA
5 5 8 13 16 51 4,87 98
Disease-free interval 21 18 21 17 13 8 3,07 98 Th. lymph node involvement
38
19
17
15
5
4
2,41
98
Number
27 28 24 10 8 1 2,46 98
Laterality 5 13 17 33 19 11 3,83 98 Liver disease
2 15 11 10 37 23 4,37 98
Responses: 98 Omissions: 14
44,9
29,6
13,3
4,1
8,2
17,0
31,9
22,3
10,6
18,1
0
5
10
15
20
25
30
35
40
45
50
Ninguna Sampling selectivo Sampling sistemático Disección ganglionarlobulo-específica
Disección ganglionarsistemática
% re
spon
ses
Resección atípica Segment. Anatómicac
10. Depending on the extent of the lung resection, what type of mediastinal lymphadenectomy do you perform more frequently in case of pulmonary metastasectomy?
Responses: 98 Omissions: 14
None Selective sampling Systematic sampling Lobe-specific Radical Lymphadenectomy
Radical Lymphadenectomy
c Wedge Anatomical resection
11. In case of, recently diagnosed, multiple and bilateral potentially resectable pulmonary metastases of CRC, what do you consider the best management?
2,1%
55,7%
42,3%
Definitive systemic therapy
Induction therapy + surgery/SBRT +/- adjuvant therapy
Surgery and/or SBRT +/- adjuvant therapy
Responses: 97 Omissions: 15
Metastatic CRC 4 Prognostic Groups with treatment implications
Lung or liver metastases are clearly resectable (R0)
At first, lung or liver metastases are not resectable (Intensive induction CT should be consider prior to potential metastasectomy)
Unresectable metastases, adequate PS and bulky, symptomatic or biologically agressive disease = intensive first-line therapy
Grupo 2
Grupo 1
Grupo 0
Grupo 3
Unresectable metastases, por PS and no present or inminent symptoms = non-intensive therapy
New-onset resectable pulmonary metastases with no-favourable prognostic factors
0,0%
13,4%
33,0%
89,7%
7,2%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
% re
spon
ses
Estabilidad en el tamaño y número demetástasis pulmonares
Aumento de tamaño de las metástasispulmonares
Aumento del número de metástasispulmonares (aun siendo factible unaresección completa de todas ellas)
Nueva aparición o progresión deenfermedad extrapulmonar
Ninguna de las situaciones anteriorescontraindicaría la cirugía pulmonar
12. In case of potentally resectable CRC pulmonary metastases treated with induction therapy, when would you rule out a subsequent surgery?
Responses: 97 Omissions: 15
PM Steady in size and number PM Increased in size PM Increased in number (although still feasible R0)
Progression or new-onset of extrapulmonary disease None of the previous would rule out surgery
13. How do you usually determine the best treatment choice for patients with CRC pulmonary metastases in your centre?
Comité Multidisciplinar de Carcinoma Colo-
Rectal; 8,3%
Comité Multidisciplinar de
Tórax (CON oncólogo médico dedicado al
carcinoma colo-rectal); 59,4%
Comité Multidisciplinar de Tórax (SIN oncólogo médico dedicado al
carcinoma colo-rectal); 28,1%
Otros ; 4,2%
Responses: 96 Omissions: 16
Others 4,2% CRC Tumour Board
8,3% Thoracic
Tumour Board (WITHOUT CRC-dedicated
oncologist) 28,1%
Thoracic Tumour Board
(WITH CRC-dedicated oncologist)
59,4%
2,2%
39,6% 36,3%
13,2%
8,8%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
Abandono de la cirugía demetástasis pulmonares
Importante disminución enla indicación quirúrgica
Moderada disminución enla indicación quirúrgica
Escasa o nula repercusiónsobre la indicación
quirúrgica
NS/NC
14. If the results of the PulMiCC trial could not ascribe a real benefit to CRC pulmonary metasectomy, what do you consider the consequences in your centre would be?
Responses: 91 Omissions: 21
No more surgery
Important decrease in surgery
Moderate decrease in surgery
Little/no decrease in surgery N/A
6,6%
31,9%
4,4%
34,1%
23,1%
0%
5%
10%
15%
20%
25%
30%
35%
40%
Biopsia líquida SBRT u otrastécnicas locales no
quirúrgicas
Nuevas técnicas deimágen
Terapias sistémicas Ensayo clínicoPulMiCC
15. Which of the following breakthroughs could influence in a shorter term on pulmonary metastasectomy practice?
Responses: 91 Omissions: 21
SBRT or other local therapies
Liquid biopsy Image Techniques
Systemic Therapies
PulMiCC Trial
16. How would you consider the inclusion of prognostic factors other than resectability in the treatment algorithms of current guidelines?
Responses: 89 Omissions: 23
Interesting 39,3%
Essential 57,3%
Superfluous 1,1%
N/A 2,2%
17. Do you consider that the development of a multidisciplinary national consensus statement could help in treatment decision-making of CRC metastatic disease?
No; 1,1%
N/A; [VALOR]
Responses: 89 Omissions: 23
Yes, and I would be delighted
to take part 71,9%
Yes, but I would not be interested in
taking part 19,1%
Predictive Model of Survival after Pulmonary Metastasectomy of Colorectal Cancer. A nationwide prospective cohort study
Disease-Specific SURVIVAL Group Median 2y DSS 95% CI 4y DSS 95% CI
1 Not reached 89 87-92 69 65-74 2 52 83 80-87 55 49-60 7 31 62 55-69 21 15-26 8 22 45 37-53 7 4-11
Extrapulm disease= History of extrapulmonary disease DFI < vs > 12 months ct-LNI= Pathological thoracic lymph node involvement
Variables in theEquation
B p HR 95,0% CI forExp(B) Lower Upper
Extrapulm disease 0,501 0,006 1,651 1,158 2,352 DFI 12m 0,7 <0,001 2,013 1,419 2,856 ct-LNI 0,77 0,009 2,159 1,211 3,852
H(t;x)=h0(t)xe(0,7xDFI + 0,77xct-LNI + 0,501xExtrapulm)